Literature DB >> 28441916

Impact of surgical margins on survival of 37 dogs with massive hepatocellular carcinoma.

A Matsuyama1, S Takagi1, K Hosoya1, Y Kagawa2, K Nakamura1, T Deguchi1, M Takiguchi1.   

Abstract

AIMS: To compare the survival of dogs with completely resected massive hepatocellular carcinoma (HCC) with that of dogs in which HCC were incompletely excised.
METHODS: A retrospective cohort study was conducted. Dogs that underwent surgical excision of massive HCC between November 2006 and April 2015 were included. Dogs that died in the perioperative period or were lost to follow-up within 2 months after surgery were excluded. Data were collected from the medical records and a single pathologist examined all available histology slides to confirm the diagnosis of HCC. Surgical margins were defined as complete if no neoplastic cells were seen at the edge of excised tissues, based on original histopathology reports. Progression-free survival (PFS) and overall survival (OS) were compared between dogs with complete surgical margins (CM) and those with incomplete margins (IM) using a log-rank test.
RESULTS: Of the 37 dogs included in the study, 25 were allocated to the CM group and 12 to the IM group. Progressive local disease developed after surgery in three dogs in the CM group and seven dogs in the IM group. Three dogs in the CM group and five dogs in the IM group died due to tumour progression. Median PFS was longer for dogs in the CM group (1,000 (95% CI=562-1,438) days) compared to dogs in the IM group (521 (95% CI=243-799) days; p=0.007). OS was also longer for dogs in the CM group (>1,836 days) compared to those in the IM group (median 765 (95% CI=474-1,056) days; p=0.02). CONCLUSIONS AND CLINICAL RELEVANCE: Compared with complete resection, incomplete resection decreased PFS and OS in dogs with massive HCC. Dogs with incompletely excised HCC should be closely monitored for local recurrence, although median OS was >2 years following incomplete excision. Further prospective studies are warranted to confirm these findings.

Entities:  

Keywords:  Canine; hepatocellular carcinoma; prognosis; surgical margins; surgical oncology

Mesh:

Year:  2017        PMID: 28441916     DOI: 10.1080/00480169.2017.1319304

Source DB:  PubMed          Journal:  N Z Vet J        ISSN: 0048-0169            Impact factor:   1.628


  7 in total

1.  Clinical impact of near-infrared fluorescence imaging with indocyanine green on surgical treatment for hepatic masses in dogs.

Authors:  Naoki Sakurai; Kumiko Ishigaki; Kazuyuki Terai; Tatsuya Heishima; Kazuki Okada; Orie Yoshida; Yumiko Kagawa; Kazushi Asano
Journal:  BMC Vet Res       Date:  2022-10-19       Impact factor: 2.792

2.  Drug-eluting bead chemoembolization for the treatment of nonresectable hepatic carcinoma in dogs: A prospective clinical trial.

Authors:  Cleo P Rogatko; Chick Weisse; Tobias Schwarz; Allyson C Berent; Marcio A Diniz
Journal:  J Vet Intern Med       Date:  2021-05-06       Impact factor: 3.333

3.  Effect of drug-eluting bead transarterial chemoembolization loaded with cisplatin on normal dogs.

Authors:  Ko Nakasumi; Naoki Yamamoto; Taro Takami; Harumichi Itoh; Kazuhito Itamoto; Hiro Horikirizono; Toshie Iseri; Munekazu Nakaichi; Yuki Nemoto; Hiroshi Sunahara; Kenji Tani
Journal:  J Vet Med Sci       Date:  2021-12-06       Impact factor: 1.267

4.  Risk factors and outcome in dogs with recurrent massive hepatocellular carcinoma: A Veterinary Society of Surgical Oncology case-control study.

Authors:  Janis M Lapsley; Vincent Wavreille; Sabrina Barry; Josephine A Dornbusch; Carolyn Chen; Haley Leeper; Judith Bertran; Diane Scavelli; Julius M Liptak; Chris Wood; Shelly Shamir; Claire Rosenbaum; Vincenzo Montinaro; Brandan Wustefeld-Janssens; Allyson Sterman; Colin Chik; Ameet Singh; Josh Collins; Laura E Selmic
Journal:  Vet Comp Oncol       Date:  2022-05-15       Impact factor: 2.385

Review 5.  Comparative Oncology: Management of Hepatic Neoplasia in Humans and Dogs.

Authors:  Erin A Gibson; Roger E Goldman; William T N Culp
Journal:  Vet Sci       Date:  2022-09-08

6.  Size of canine hepatocellular carcinoma as an adverse prognostic factor for surgery.

Authors:  Yury Vatnikov; Ilya Vilkovysky; Evgeny Kulikov; Irina Popova; Nadia Khairova; Aleksey Gazin; Andrey Zharov; Darya Lukina
Journal:  J Adv Vet Anim Res       Date:  2020-02-06

7.  Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody.

Authors:  Gang Liu; Wenxuan Zhou; Xiaoli Li; Lijie Guo; Tingting He; Juan Zhao; Liansheng Gong
Journal:  Front Immunol       Date:  2021-08-24       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.